Pfaus James G, Shadiack Annette, Van Soest Tanya, Tse Maric, Molinoff Perry
Center for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montreal, QC, Canada H4B 1R6.
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10201-4. doi: 10.1073/pnas.0400491101. Epub 2004 Jun 28.
Disorders of sexual desire affect an estimated 30% of women in North America and Europe, with etiologies based on interpersonal, personal, and physiological factors. There are currently no pharmacological agents approved for use in the treatment of female sexual dysfunction. This is due, in part, to a focus on the effects of experimental drugs on reflexive components of sexual behavior, such as lordosis, in animal models. Here we report that PT-141, a peptide analogue of alpha-melanocyte-stimulating hormone that binds to central melanocortin receptors, selectively stimulates solicitational behaviors in the female rat. This occurs without affecting lordosis, pacing, or other sexual behaviors. PT-141 did not cause generalized motor activation, nor did it affect the perception of sexual reward. A selective pharmacological effect on appetitive sexual behavior in female rats has not been reported previously, and indicates that central melanocortin systems are important in the regulation of female sexual desire. Accordingly, PT-141 may be the first identified pharmacological agent with the capability to treat female sexual desire disorders.
据估计，北美和欧洲有30%的女性存在性欲障碍，其病因基于人际、个人和生理因素。目前尚无被批准用于治疗女性性功能障碍的药物。部分原因在于，在动物模型中，研究重点一直放在实验药物对性行为反射成分（如脊柱前凸）的影响上。在此我们报告，PT - 141是一种与中枢黑皮质素受体结合的α - 黑素细胞刺激激素的肽类似物，它能选择性地刺激雌性大鼠的求偶行为。这种情况不会影响脊柱前凸、踱步或其他性行为。PT - 141不会引起全身性运动激活，也不会影响对性奖励的感知。此前尚未报道过对雌性大鼠性欲性行为有选择性药理作用的情况，这表明中枢黑皮质素系统在调节女性性欲方面很重要。因此，PT - 141可能是首个被确认有能力治疗女性性欲障碍的药物。
